157893-14-6

Basic information

• Product Name: 3-BROMO-5-METHOXYBENZOIC ACID
• Synonyms: 5-BROMO-3-METHOXYBENZOIC ACID;3-BROMO-5-METHOXYBENZOIC ACID;3-Bromo-5-methoxybenzoic acid 99%;3-Bromo-5-carboxyanisole;3-Bromo-5-carboxyanisole, 5-Bromo-m-anisic acid
• CAS NO: 157893-14-6
• Molecular Formula: C₈H₇BrO₃
• Molecular Weight: 231.04
• Product Categories: Aromatic Carboxylic Acids, Amides, Anilides, Anhydrides & Salts
• Mol File: 157893-14-6.mol

Chemical Properties

• Melting Point: 190-191 °C(Solv: ethanol (64-17-5))
• Boiling Point: 338.8 °C at 760 mmHg
• Flash Point: 158.7 °C
• Appearance: /
• Density: 1.625 g/cm³
• Vapor Pressure: 3.74E-05mmHg at 25°C
• Refractive Index: 1.583
• Storage Temp.: Room temperature.
• PKA: 3.69±0.10(Predicted)
• CAS DataBase Reference: 3-BROMO-5-METHOXYBENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-5-METHOXYBENZOIC ACID(157893-14-6)
• EPA Substance Registry System: 3-BROMO-5-METHOXYBENZOIC ACID(157893-14-6)

Safety Data

• Hazardous Substances Data: 157893-14-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-5-methoxybenzoic acid is utilized as an intermediate in the synthesis of various pharmaceuticals. Its presence in the molecular structure of target compounds contributes to their therapeutic properties, making it an essential component in drug development.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Bromo-5-methoxybenzoic acid serves as a key intermediate in the production of agrochemicals. Its integration into the molecular frameworks of these chemicals enhances their effectiveness in agricultural applications, such as pest control and crop protection.
Used in Chemical Industry:
3-Bromo-5-methoxybenzoic acid is employed as a building block in the chemical industry for the production of a variety of organic compounds. Its structural features facilitate the formation of complex molecules, which are vital for numerous chemical processes and end products.
Overall, 3-Bromo-5-methoxybenzoic acid's diverse applications in different industries underscore its importance as a chemical intermediate and building block, highlighting its role in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds.

InChI:InChI=1/C8H7BrO3/c1-12-7-3-5(8(10)11)2-6(9)4-7/h2-4H,1H3,(H,10,11)

Upstream product

• 140472-69-1 3-bromo-5-hydroxy-benzoic acid 
• 77-78-1 dimethyl sulfate 
• 29578-83-4 3-bromo-5-methoxytoluene 
• 867366-91-4 3-bromo-5-methoxybenzonitrile 
• 864293-44-7 2-amino-5-bromo-3-methoxy benzoic acid 
• 6303-21-5 hypophosphorous acid 
• 618-58-6 3,5-dibromobenzoic acid 
• 124-41-4 sodium methylate 
• 3177-80-8 2-amino-3-methoxybenzoic acid 

Downstream Products

• 1261582-04-0 3-bromo-5-methoxybenzoyl chloride 
• 56709-70-7 3-bromo-5-methoxy-benzoic acid methyl ester 
• 262450-64-6 (3-bromo-5-methoxyphenyl)methanol 
• 586-38-9 3-Methoxybenzoic acid 
• 936728-20-0 3-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid 
• 1186516-74-4 (R)-3-methoxy-5-(5-methylpyridin-2-yl)-N-(1-(2-methylpyrmiidin-5-yl)ethyl)benzamide 
• 1186519-10-7 methyl 3-methoxy-5-(5-methylpyridin-2-yl)benzoate 
• 1186519-11-8 3-methoxy-5-(5-methylpyridin-2-yl)benzoic acid 
• 1422695-15-5 3-bromo-5-((tert-butyldimethylsilyl)oxy)-N,N-diisopropylbenzamide 

Relevant articles and documents

Synthesis of novel benzbromarone derivatives designed to avoid metabolic activation

We synthesized six novel BBR derivatives that were designed to avoid metabolic activation via ipso-substitution and evaluated for their degree of toxicity and hURAT1 inhibition. It was found that all of the derivatives demonstrate lower cytotoxicity in mouse hepatocytes and lower levels of metabolic activation than BBR, while maintaining their inhibitory activity toward the uric acid transporter. We propose that these derivatives could serve as effective uricosuric agents that have much better safety profiles than BBR.

Bifunctional organocatalysts for the asymmetric synthesis of axially chiral benzamides

Bifunctional organocatalysts bearing amino and urea functional groups in a chiral molecular skeleton were applied to the enantioselective synthesis of axially chiral benzamides via aromatic electrophilic bromination. The results demonstrate the versatilit

COMBINATION THERAPIES FOR TREATMENT OF CANCER

Combination therapies for treatment of cancers associated with mutations in the KRAS gene are provided. Compositions comprising therapeutic agents for treatment of cancers associated with mutations in the KRAS gene are also provided.

Use of Inhibitors of the Activity or Function of PI3K

The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject.

COVALENT INHIBITORS OF KRAS G12C

Irreversible inhibitors of G12C mutant K-Ras protein are provided. Also disclosed are methods to modulate the activity of G12C mutant K-Ras protein and methods of treatment of disorders mediated by G12C mutant K-Ras protein.

QUINAZOLINE DERIVATIVES AS PI3K MODULATORS

The invention relates to substituted quinazoline derivative of the formula (I), wherein A, X1, X2, X3, X4 and R5 are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.

Use of inhibitors of the activity or function of PI3K

The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject.

AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF

Compounds are provided according to formula (1 ) : where A, B, W, X', L, R1, R3, R4b, and m' are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others.

DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS

The present invention is directed to novel compounds of Formula's (I) - (VI), and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of and/or prophylaxis of respiratory diseases, including inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention is directed to novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use as dual chromaphores having inhibitory activity against PDE4 and muscarinic acetylcholine receptors (mAChRs), and thus being useful for treating respiratory diseases.